United States

S. 4472

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Health, Education, Labor, and Pensions Committee · Sen. Lisa Murkowski (R-AK)

The bill would extend funding through fiscal year 2031 for federal research and development programs aimed at finding treatments for ALS and other neurodegenerative diseases, including grants from the National Institutes of Health and Food and Drug Administration as well as a public-private partnership supporting drug development. It would also add new requirements for tracking the safety and effectiveness of investigational drugs, ensure timely reporting of clinical trial safety data, require the FDA to publish five-year development plans for neurodegenerative disease treatments every five years, and mandate reports on the program's impact.[AI-Generated]

Passed Senate with amendment (voice vote) 4 August 2026

Record as of 10 August 2026 — the most recent action in the official record. Status can lag; each step below carries its own date.

10 August 2026 Held at the desk.
2 more actions
1. 10 August 2026 Received in the House.
2. 10 August 2026 Message on Senate action sent to the House.
4 August 2026 Passed Senate with amendment (voice vote)
16 July 2026 Placed on calendar (Senate)
16 July 2026 Reported by committee
1 more action
1. 17 June 2026 Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
30 April 2026 Referred to committee
30 April 2026 Introduced in Senate

This path starts where the bill does — its first action in the official record. Routine procedural steps sit in the “more actions” rows above rather than on the main line.

Read the live feed — on the site or in the app Look up S. 4472 on Congress.gov All US bills